Navigation Links
Newly Labeled Therapies for Neuropathic Pain, Including Drugs From Pfizer and Eli Lilly, Will Drive Growth in the Chronic Pain Drug Market
Date:3/10/2008

Following Recovery From Withdrawal of Two COX-2 Inhibitors, the Chronic Pain Drug Market Will Regain Momentum, According to a New Report from

Decision Resources

WALTHAM, Mass., March 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that market penetration of drugs that have been newly labeled to treat neuropathic pain, including Pfizer's Lyrica and Eli Lilly's Cymbalta will be a key driver of growth in the chronic pain drug market through 2016.

The new Pharmacor report entitled Chronic Pain finds that, following recovery from the withdrawals in 2004 and 2005 of two COX-2 inhibitors, the chronic pain market will regain momentum over the next decade, with 5 to 6% annual growth in total sales in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

"In contrast to older established drugs like amitriptyline, new agents such as Lyrica and Cymbalta have the safety and efficacy data from large-scale clinical trials that will allow them to compete in this market," said Kate Hohenberg, director at Decision Resources. "Both of these drugs will achieve blockbuster status in the chronic pain drug market by 2011 and sales of Lyrica will exceed $2 billion by 2016."

The chronic pain drug market in Japan will be particularly robust from 2011 to 2016 as drugs that include Cymbalta, Lyrica and Endo's Lidoderm reach that market. Also driving growth in Japan will be Pfizer's Celebrex which reached the Japanese market in 2007. The report also finds that the continued use of opioid analgesics for chronic, non-cancer pain and the introduction of more-tolerable, safer opioid formulations in the next five years will drive opioid analgesic sales for chronic pain to more than $6 billion by 2016 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

About Chronic Pain

Key chronic pain populations, which account for approximately 80% of the drug market for chronic pain therapies and are covered in the report, include arthritic pain, chronic low back pain, fibromyalgia, diabetic neuropathic pain, postherpetic neuralgia, HIV-related neuropathic pain, chronic headache (including transformed migraine) and cancer pain. Sales of drugs to treat these and other, less clearly defined chronic pain conditions exceeded $14 billion in 2006 in the world's major pharmaceutical markets.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. First study examines newly-licensed RN work attitudes and intentions
2. Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction
3. Higher death rates in kidney patients with newly recognized disease
4. Newly Published Study in Leading Medical Journal Further Confirms the Brava Systems Non-Surgical Breast Enhancement Effectiveness
5. Natural Nutrition Expands Revenue Capabilities with Newly Installed State of the Art Nutrition Bar Line
6. Corrected & Replaced - Natural Nutrition Expands Revenue Capabilities with Newly Installed State of the Art Nutrition Bar Line
7. Hidden Costs Plague Owners Occupying Newly Constructed Buildings; New Program Can Help Avoid Major Issues
8. Striking shift seen among newly HIV-infected men regarding partners
9. Newly HIV-Infected Gay Men Select Other Infected Partners
10. Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
11. New therapeutic options for newly diagnosed multiple myeloma patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... Roxanna Cross ... p.m. at the 11th Annual RISE Nashville Summit. RISE Nashville is the healthcare ... and engagement strategies. , The discussion will include best practices for accurate identification ...
(Date:2/27/2017)... ... February 27, 2017 , ... Robert E. Burke, MD, PhD, ... But his impoverished upbringing and life experiences could have led him down a much ... and Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares a personal account ...
(Date:2/27/2017)... ... ... Carothers is not your typical author. She went from working as a movie extra on ... God, when she isn’t swimming as a performing mermaid. , Her book isn’t typical either. ... offers a comedic look at the dysfunctions of God’s family, before Lucifer was sent to ...
(Date:2/27/2017)... POUGHKEEPSIE, N. Y. (PRWEB) , ... February 27, 2017 , ... ... Society ( ILADS ) has disclosed that despite scientific studies, the Center for Disease ... of chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, a ... an upgrade to the company's Yelp listing. Bay Area residents struggling from thinning ... as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular Unit ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... marks the passing of one if its founding fathers, Dr. Eugene ... the service of scientific and scholarly research. A pioneer in the practice ... the way researchers work with the literature, Garfield passed away suddenly on ... ... Dr. Eugene Garfield, founding father ...
(Date:2/28/2017)... This report provides all the information you ... and activities since 2010. Download the full ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
(Date:2/28/2017)...   Fourth-quarter 2016 revenues ... million to top end of guidance ... charges in fourth-quarter 2016 associated with the write-down of ... Generics reporting unit Fourth-quarter ... operations; Full-year 2016 reported $14.48 diluted (GAAP) loss per ...
Breaking Medicine Technology: